David A Fullerton Selected Research

Secretory Phospholipases A2

1/2021	Secretory Phospholipase A2 Inhibition Attenuates Adhesive Properties of Esophageal Barrett's Cells.
1/2021	Secretory Phospholipase A2 IIa Mediates Expression of Growth Factor Receptors in Esophageal Adenocarcinoma.
6/2019	Inhibition of secretory phospholipase A2 IIa attenuates prostaglandin E2-induced invasiveness in lung adenocarcinoma.
8/2014	Cancer stem cell phenotype is supported by secretory phospholipase A2 in human lung cancer cells.
4/2013	Secretory phospholipase A2 mediates human esophageal adenocarcinoma cell growth and proliferation via ERK 1/2 pathway.
12/2012	Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.
11/2012	Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo.
9/2012	Group IIa sPLA2 inhibition attenuates NF-κB activity and promotes apoptosis of lung cancer cells.
2/2012	Lung cancer cell invasion and expression of intercellular adhesion molecule-1 (ICAM-1) are attenuated by secretory phospholipase A₂ inhibition.
5/2011	Secretory phospholipase A2 inhibition attenuates intercellular adhesion molecule-1 expression in human esophageal adenocarcinoma cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David A Fullerton Research Topics

Disease

16	Inflammation (Inflammations) 01/2022 - 08/2007
16	Ischemia 01/2022 - 05/2008
14	Neoplasms (Cancer) 01/2022 - 03/2010
13	Reperfusion Injury 01/2019 - 06/2008
12	Spinal Cord Ischemia 01/2022 - 01/2011
10	Adenocarcinoma 10/2022 - 03/2010
9	Lung Neoplasms (Lung Cancer) 02/2021 - 02/2012
8	Aortic Valve Stenosis (Aortic Stenosis) 01/2022 - 01/2008
7	Myocardial Ischemia (Ischemic Heart Diseases) 03/2016 - 08/2002
5	Hyperplasia 10/2022 - 12/2009
5	Stroke (Strokes) 01/2022 - 05/2013
5	Paraplegia (Spastic Paraplegia) 03/2015 - 01/2011
4	Infections 01/2022 - 01/2006
4	Barrett Esophagus (Barrett's Esophagus) 01/2021 - 12/2009
4	Adenocarcinoma of Lung 10/2020 - 02/2012
4	Aortic Valve Disease 01/2017 - 11/2012
3	Infarction (Infarctions) 01/2022 - 12/2011
3	Spinal Cord Injuries (Spinal Cord Injury) 10/2021 - 01/2011
3	Chronic Obstructive Pulmonary Disease (COPD) 10/2020 - 04/2008
3	B-Cell Lymphoma (Lymphoma, B Cell) 12/2018 - 01/2014
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2015 - 09/2012
3	Endotoxemia 09/2014 - 06/2007
3	Gastroesophageal Reflux (GERD) 03/2010 - 06/2008
2	Carcinogenesis 01/2022 - 06/2008
2	Esophageal Neoplasms (Esophageal Cancer) 01/2021 - 05/2011
2	Hypertension (High Blood Pressure) 10/2020 - 10/2019
2	Metaplasia 01/2019 - 06/2008
2	Sclerosis 06/2017 - 01/2017
2	Vascular Calcification 11/2015 - 04/2011
2	Neoplasm Metastasis (Metastasis) 09/2012 - 02/2012
2	Atherosclerosis 11/2011 - 12/2010
2	Hemorrhagic Shock 08/2007 - 03/2005
1	Respiratory Insufficiency (Respiratory Failure) 05/2022
1	COVID-19 01/2022
1	Acute Kidney Injury (Acute Renal Failure) 01/2022
1	Esophageal Diseases 01/2022

Drug/Important Bio-Agent (IBA)

11	Secretory Phospholipases A2IBA 01/2021 - 12/2009
8	Toll-Like Receptor 4IBA 01/2022 - 03/2005
8	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2022 - 01/2008
8	Proteins (Proteins, Gene)FDA Link 01/2020 - 06/2008
7	Phospholipases (Phospholipase)IBA 04/2013 - 06/2008
6	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2022 - 06/2007
5	Simvastatin (Zocor)FDA LinkGeneric 10/2022 - 11/2011
5	salicylhydroxamic acid (SHAM)IBA 01/2022 - 01/2011
5	Erythropoietin FDA Link 12/2018 - 01/2011
5	EnzymesIBA 01/2017 - 06/2008
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2011 - 03/2005
4	oxidized low density lipoproteinIBA 01/2017 - 04/2011
4	CytokinesIBA 01/2017 - 05/2008
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2022 - 11/2011
3	Nicorandil (SG 75)IBA 01/2022 - 01/2021
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 03/2016
3	Diazoxide (Hyperstat)FDA Link 10/2021 - 01/2018
3	Phosphotransferases (Kinase)IBA 01/2021 - 03/2015
3	NF-kappa B (NF-kB)IBA 01/2021 - 05/2008
3	Oxygen (Dioxygen)IBA 05/2015 - 08/2007
3	BiglycanIBA 04/2015 - 11/2012
3	Dexmedetomidine FDA Link 04/2014 - 11/2012
2	CreatinineIBA 01/2022 - 01/2021
2	Deoxycholic Acid (Sodium Deoxycholate)IBA 01/2022 - 01/2022
2	CollagenIBA 01/2022 - 06/2017
2	Potassium Channels (Potassium Channel)IBA 10/2021 - 01/2021
2	Adenosine Triphosphate (ATP)IBA 10/2021 - 01/2021
2	SolutionsIBA 01/2021 - 01/2021
2	Atorvastatin (Lipitor)FDA Link 01/2021 - 11/2011
2	ErbB Receptors (EGF Receptor)IBA 01/2021 - 12/2012
2	Matrilin ProteinsIBA 01/2020 - 01/2017
2	Neuroprotective AgentsIBA 12/2018 - 01/2018
2	InterleukinsIBA 01/2017 - 05/2008
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 03/2015 - 01/2014
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2015 - 09/2014
2	LipopolysaccharidesIBA 04/2014 - 07/2008
2	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 01/2014 - 04/2013
2	CalciumIBA 06/2013 - 07/2008
2	Messenger RNA (mRNA)IBA 12/2012 - 11/2012
2	Hematoxylin (Haematoxylon)IBA 11/2012 - 06/2008
2	Group II Phospholipases A2IBA 11/2012 - 09/2012
2	Eosine Yellowish-(YS) (Eosin)IBA 11/2012 - 06/2008
2	AcidsIBA 05/2011 - 04/2010
2	Hemoglobins (Hemoglobin)IBA 04/2009 - 08/2007
1	KATP ChannelsIBA 01/2022
1	Warfarin (Coumadin)FDA LinkGeneric 01/2022
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2022
1	Matrix Metalloproteinases (MMPs)IBA 01/2022
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2021
1	2- phenyl- 4,4,5,5- tetramethylimidazoline- 1- oxyl- 3- oxideIBA 10/2021
1	Saline SolutionIBA 10/2021
1	1,3- dihydroxy- 4,4,5,5- tetramethyl- 2- (4- carboxyphenyl)tetrahydroimidazole (NOR 1)IBA 10/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021

Therapy/Procedure

10	Therapeutics 10/2020 - 01/2011
5	Lung Transplantation 05/2022 - 04/2008
4	Length of Stay 01/2022 - 01/2020
3	Transplantation 01/2022 - 09/2014
3	Injections 01/2021 - 08/2002
3	Cardiopulmonary Bypass (Heart-Lung Bypass) 01/2020 - 01/2006
2	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 10/2019 - 10/2013
2	Sternotomy 07/2015 - 01/2006
1	Heart Transplantation (Grafting, Heart) 01/2022
1	Organ Transplantation 01/2022
1	Segmental Mastectomy (Lumpectomy) 02/2021